Natco Pharma to Acquire Majority Stake in South Africa’s Adcock Ingram for Approx. USD 240 Million

In a major cross-border pharmaceutical deal, India’s Natco Pharma has announced the acquisition of significant stakes in South Africa’s Adcock Ingram in a transaction valued at Approx. USD 240 Million. The move will transition the 135-year-old Adcock Ingram into a privately held company jointly owned by Natco and Bidvest, which will retain its position as the majority shareholder.

Shareholder Approval and Delisting

The acquisition was approved following a shareholder meeting where more than 98% voted in favor of Natco’s proposal to acquire all ordinary shares, excluding those already held by Natco, Bidvest, and treasury shares. This approval paves the way for Adcock Ingram’s delisting from the Johannesburg Securities Exchange (JSE).

Strengthening Global Footprint

Founded in 1890, Adcock Ingram has evolved from a small pharmacy into one of South Africa’s leading pharmaceutical firms, offering a diverse portfolio spanning prescription, OTC, consumer, and hospital products. The acquisition marks a significant step for Natco Pharma as it strengthens its footprint in the African market and aligns with its strategy to expand globally through strategic partnerships and acquisitions.